RecruitingMetastatic Solid TumorLocally Advanced Solid Tumor
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment. Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.
Sponsor: University of Utah
You may qualify if…
- ✓ Participant aged ≥ 18 years
- ✓ Histologically confirmed solid tumor.
- ✓ Radiologically confirmed locally advanced or metastatic disease.
- ✓ Eligible for and willing to receive treatment with panitumumab or cetuximab as standard-of-care.
- ✓ ECOG Performance Status ≤ 2.
- ✓ Adequate organ function as defined as:
- ✓ -Hepatic:
- ✓ Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)
You may not qualify if…
- ✕ Treatment with an anti-EGFR agent within 90 days of registration.
- ✕ Pre-existing facial rash that per the treating investigator would preclude the ability to assess response to topical tretinoin.
- ✕ The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6).
- ✕ Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
- ✕ Systemic active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.
- ✕ -Note: Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- ✕ Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.
- ✕ Known prior severe hypersensitivity to investigational product or any component in its formulations (CTCAE v5.0 Grade ≥ 3).
Where it's recruiting
Utah
Salt Lake City
Source: ClinicalTrials.gov · NCT06358677 · last updated 2026-02-13